Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Sues Amphastar for Enox Infringement as Copaxone Suit Hearing Ends
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 5 | New: 17
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $15.00.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone potential, biosimilars. We think m-enox sales revenue to MNTA will decline rapidly from Q4/11 on Amphastar’s enox launch. We still think that the recently completed Teva generic Copaxone infringement trial will result in MNTA/Sandoz’s favor (we think mid-2012) and that MNTA will become a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $10.62 yesterday.
Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on generic Copaxone potential, biosimilars. We think m-enox sales revenue to MNTA will decline rapidly from Q4/11 on Amphastar’s enox launch. We still think that the recently completed Teva generic Copaxone infringement trial will result in MNTA/Sandoz’s favor (we think mid-2012) and that MNTA will become a biosimilars development leader."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $10.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- RBC Capital Downgrades Super Retail Group Ltd. (SUL:AU) to Sector Perform
- Canaccord Downgrades Northern Star Resources (NST:AU) (NESRF) to Hold
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
